БОЛЕЗНЬ КРОНА: СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О ПАТОГЕНЕЗЕ, ДИАГНОСТИКЕ И ЛЕЧЕНИИ

Authors

  • Бахтиёров Дониёрбек Author
  • Ахмадалиев Исомиддин Author

Keywords:

Crohn's disease, inflammatory bowel disease, pathogenesis, diagnosis, biological therapy, TNF-α inhibitors, JAK inhibitors, upadacitinib, IL-23 inhibitors, gut microbiota dysbiosis

Abstract

This literature review systematizes current data on Crohn's disease (CD) — a chronic inflammatory bowel disease characterized by transmural, segmental, granulomatous inflammation. Based on publications from 2020 to 2025, including clinical guidelines of the Russian Ministry of Health (2024), ECCO recommendations, and data from randomized clinical trials, the review addresses epidemiology, key pathogenetic mechanisms (genetic factors, microbiota dysbiosis, innate immune dysfunction), conventional diagnostic and therapeutic approaches, and emerging targeted therapies including IL-23 inhibitors and JAK inhibitors. Special attention is given to the top-down treatment strategy and the treat-to-target concept aimed at mucosal healing. The expanding therapeutic arsenal for Crohn's disease creates new opportunities for personalized patient management.

References

1. Клинические рекомендации «Болезнь Крона». Минздрав РФ. — 2024. — ID: 176_2.

2. Клинические рекомендации «Болезнь Крона» (дети). Минздрав РФ. — 2024. — ID: 682_2.

3. Caron B., Honap S., Peyrin-Biroulet L. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies // Journal of Crohn's and Colitis. — 2024. — Vol. 18, Suppl. 2. — P. ii3–ii15. DOI: 10.1093/ecco-jcc/jjae082.

4. Benchimol E.I. et al. The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD // Journal of the Canadian Association of Gastroenterology. — 2023.

5. Quaglia M. et al. NOD2 and Crohn's Disease Clinical Practice // Inflammatory Bowel Diseases. — 2025. — Vol. 31, No. 2. — P. 552–562. DOI: 10.1093/ibd/izae075.

6. Ungaro R. et al. Novel and emerging drugs for the treatment of Crohn's disease: a review of phase II and III trials // Expert Opinion on Emerging Drugs. — 2024. DOI: 10.1080/14728214.2024.2303947.

7. Masri L. et al. Advancements in Targeted Therapies for the Management of Crohn's Disease: A Comprehensive Review // Journal of Clinical Medicine. — 2024. PMC11226209.

8. Honap S. et al. Unveiling the Potential of JAK Inhibitors in Inflammatory Bowel Disease // Biologics. — 2024. — Vol. 4, No. 2. — P. 177–186. DOI: 10.3390/biologics4020012.

9. Noor N.M. et al. Safety and Efficacy of Upadacitinib in Crohn's Disease: An Updated Systematic Review // PMC. — 2024. PMC11506236.

10. Gorski T. et al. Biological Therapy and Small Molecules for Adults With Crohn's Disease: Systematic Review and Network Meta-Analysis // Pharmacotherapy. — 2025. DOI: 10.1002/phar.70049.

Published

2026-05-15